BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

BioAge Labs

BioAge Labs logo

Founded
2015
Geography
United States of America based
Funding
$123.900 M

BIOAGE develops drugs to treat aging and its associated diseases. We are backed by Andreessen Horowitz, AME Cloud Ventures, PEAR Ventures, Felicis Ventures, Caffeinated Capital, and others. We have created a unique computational platform that leverages proprietary omics data from large human cohorts to identify the molecular pathways that influence longevity. We then develop drugs that target these pathways and treat specific age-related diseases.


aging biomarkers

Technologies

AI Companies (Drug Discovery)   Aging Research  


Posts Mentioning This Company

R&D Platform

Analyze omics data related to aging. Allows researchers to: Develop biomarkers and drugs that impact human aging.


BIOAGE

Read more

Pipelines

BGE-117
Clinical  |  Visit website

BGE-117: BIOAGE’S FIRST CLINICAL-STAGE ASSET TARGETS HIF SIGNALLING
A core longevity pathway that drives regeneration, healing, and resilience
The Hypoxia-inducible factor (HIF) pathway is linked to lifespan and healthspan in BioAge’s proprietary human aging data. Pathway activation levels are significantly associated with longevity and multiple functional measures. BGE-117 is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor that can potentially treat multiple diseases of aging through the activation of HIF-1 target genes that are involved in numerous biological processes including tissue regeneration, erythropoiesis, glycolysis, glucose uptake, vascular remodeling and angiogenesis.

BGE-175
Clinical  |  Visit website

The molecular pathways impacted by BGE-175 are linked to lifespan and healthspan in BioAge’s proprietary human aging data. The prostaglandin pathway, as well as several key components of the immune response to viral challenge, are significantly associated with longevity and multiple functional measures. Inhibition of PGD2 DP1 receptor signaling impacts multiple immune mechanisms, including activation of dendritic cells and NK cells, and reducing neutrophil infiltration. Preclinical studies demonstrate that BGE-175 inhibits neutrophil migration and that DP1 inhibition boosts dendritic cell function, both of which counteract known aspects of immune aging, and are also therapeutically promising for COVID-19 and other respiratory infections.

BGE-105
Clinical  |  Visit website

Apelin is a small secreted peptide hormone that regulates multiple aspects of muscle physiology, including cell growth and survival, regeneration, and repair. BioAge’s analysis of our proprietary longitudinal aging data revealed that higher apelin signaling activity correlates with improved muscle function, reduced frailty, and longer lifespan. Apelin levels decline with age, and activation of apelin signaling reverses age-related sarcopenia in mice. BGE-105, an oral agonist of the apelin receptor APJ, could ameliorate muscle aging, which causes loss of strength, mobility, and function, driving mortality and multiple age-related diseases. By targeting this fundamental mechanism of aging, BGE-105 could treat multiple acute and chronic indications: improving muscle strength in frail patients, accelerating rehabilitation following fractures, and increasing mobility after extended bed rest.

Products

 

Services

No services posted yet